Blog: A Bumpy, Slow Transformation to Biomaterials?

8:32 AM MDT | October 18, 2010 | Alex Scott

Although it is widely accepted that one day cheap oil will run out, even in a world of seemingly generous government funding some biomaterial technology providers are struggling to deliver the solutions while maintaining profitability. Verenium (Cambridge, MA), a biotech firm, could be one such company: Laurence Alexander, an analyst with investment bank Jefferies and Company (New York), in a recent report, downgraded forecast 2010 earnings per share for Verenium from $0.35 to a loss of $2.2. Alexander doesn’t opt for a positive stance in 2011...